<p>周四午盘，礼来公司（NYSE:LLY）股价上涨 0.6%。股价最高达到 878.09 美元，最后交易价为 872.34 美元。约 603,843 股股票在交易中换手，较日均成交量 2,942,490 股下降了 79%。股价前一交易日收盘价为 867.30 美元。</p>
<p>获取 <strong>礼来公司</strong> 的提醒：</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>Hims &amp; Hers Health 因通用 GLP-1 推出计划而飙升</li>
</ul>
<p>LLY 股票近期成为多份研究报告的讨论焦点。坎特菲茨杰尔德（Cantor Fitzgerald）重申对礼来公司的 “超重” 评级，并在周二的研究报告中给出了每股 885.00 美元的目标价位。根据 2 月 16 日星期五的一份报告，摩根士丹利（Morgan Stanley）将礼来公司的目标价从 805.00 美元上调至 950.00 美元，并给予该公司 “超重” 评级。阿格斯（Argus）将礼来公司的目标价从 770.00 美元提高至 840.00 美元，并在 5 月 14 日星期二的研究报告中给予该公司 “买入” 评级。Truist Financial 将礼来公司的目标价从 850.00 美元上调至 892.00 美元，并在 5 月 1 日星期三的报告中给予该公司 “买入” 评级。最后，杰富瑞金融集团（Jefferies Financial Group）将礼来公司的目标价从 925.00 美元上调至 957.00 美元，并在 6 月 7 日星期五的报告中给予该公司 “买入” 评级。三位研究分析师对该股票给予持有评级，而 17 位对该公司股票给予买入评级。根据 MarketBeat 的数据，礼来公司目前的共识评级为 “中度买入”，平均目标价为 787.53 美元。</p>
<p><strong>查看我们对礼来公司的最新股票分析</strong></p>
<h2>礼来公司股价上涨 1.1%</h2>
<ul>
<li>尽管市场疲软，4 只股票创下新高</li>
</ul>
<p>该公司当前比率为 1.35，速动比率为 1.03，负债权益比为 1.90。公司的 50 天简单移动平均线为 781.80 美元，200 天简单移动平均线为 714.39 美元。公司市值为 8332.3 亿美元，市盈率为 129.19，市盈增长比率为 1.89，贝塔系数为 0.36。</p>
<p>礼来公司（NYSE:LLY）于 5 月 6 日星期一发布了季度收益报告。公司报告季度每股盈利为 2.58 美元，超过分析师预期的 2.53 美元，超出 0.05 美元。礼来公司的净利润率为 17.08%，净资产收益率为 56.98%。该季度公司收入为 877 亿美元，低于分析师预期的 894 亿美元。与去年同期相比，该季度业务收入增长了 26.0%。股票分析师平均预计，礼来公司今年将实现每股盈利 13.76 美元。</p>
<h2>礼来公司宣布股息</h2>
<ul>
<li>LifeMD 因其 GLP-1 产品而大涨</li>
</ul>
<p>公司最近宣布了季度股息，股息于 6 月 10 日星期一支付。截至 5 月 16 日星期四持股的股东将获得 1.30 美元的股息。这代表每年 5.20 美元的股息和股息率为 0.59%。除息日为 5 月 15 日星期三。礼来公司的股息支付比率为 76.58%。</p>
<h2>内部交易活动</h2>
<p>在其他礼来公司新闻中，主要股东礼来基金会（Lilly Endowment Inc）于 5 月 24 日星期五以 809.21 美元的平均价格出售了 92,563 股股票。交易总额为 74,902,905.23 美元。交易后，该内部人士现在直接持有公司中的 98,556,247 股股票，价值约 79,752,700,634.87 美元。该交易已在提交给证券交易委员会的文件中披露，可通过此超链接访问。此外，首席会计官唐纳德·A·扎克罗斯基（Donald A. Zakrowski）于 6 月 3 日星期一以 819.47 美元的平均价格出售了 750 股公司股票。交易总额为 614,602.50 美元。交易完成后，首席会计官现在持有公司 7,130 股股票，价值约 5,842,821.10 美元。该交易已在提交给证券交易委员会的文件中披露，可通过此超链接访问。此外，主要股东礼来基金会于 5 月 24 日星期五以 809.21 美元的平均价格出售了 92,563 股公司股票。交易总额为 74,902,905.23 美元。交易完成后，该内部人士现在持有公司 98,556,247 股股票，价值 79,752,700,634.87 美元。有关此次交易的披露可在此处找到。过去 90 天内，内部人士已出售 552,804 股价值 462,119,714 美元的公司股票。公司内部人士持有公司股票的比例为 0.13%。</p>
<h2>礼来公司的机构交易</h2>
<p>最近，许多机构投资者对礼来公司的持股进行了调整。Vanguard Group Inc.在第一季度将其在礼来公司的持股比例提高了 1.6%。Vanguard Group Inc.在上个季度购买了额外的 1,133,810 股股票后，现在拥有公司的 72,745,011 股股票，价值 565.92709 亿美元。Capital World Investors 在第四季度将其对礼来公司股票的持股比例提高了 0.3%。Capital World Investors 在上个季度购买了额外的 89,720 股股票后，现在拥有公司的 26,949,773 股股票，价值 157.09466 亿美元。摩根士丹利在第三季度将其对礼来公司股票的持股比例提高了 0.7%。摩根士丹利在该期间购买了额外的 83,915 股股票后，现在拥有公司的 12,545,572 股股票，价值 67.38605 亿美元。挪威中央银行在第四季度收购了价值 59.9289 亿美元的礼来公司新股份。最后，Northern Trust Corp 在第三季度将其对礼来公司的持股比例提高了 3.6%。Northern Trust Corp 在上个季度额外增持了 355,317 股股票后，现在拥有公司的 10,158,275 股股票，价值 54.56314 亿美元。机构投资者和对冲基金拥有公司股份的 82.53%。</p>
<h2>礼来公司公司简介（获取免费报告）</h2>
<p>礼来公司在全球范围内发现、开发和销售人类药品。该公司为糖尿病提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素利斯普罗、胰岛素利斯普罗胺、胰岛素利斯普罗混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500；为 2 型糖尿病提供 Jardiance、Mounjaro 和 Trulicity；为肥胖症提供 Zepbound。</p>
<h2>推荐故事</h2>
<ul>
<li>五支我们比礼来公司更喜欢的股票</li>
<li>如何使用 MarketBeat Excel 股息计算器</li>
<li>戴夫与巴斯特股票提供了一个主要的购买机会</li>
<li>股息支付比率计算器</li>
<li>FOMC 决定意味着今年夏天股票价格上涨</li>
<li>股息捕捉策略：你需要了解的</li>
<li>分析师为什么提高了沃尔玛股票的估值</li>
</ul>
<p><em>这则即时新闻警报是由 Narrative Science 技术和 MarketBeat 的财务数据生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队的审核。请将有关本故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 这个 10 万亿美元科技繁荣的关键（来自 Porter &amp; Company）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MzM4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MzM4"/></p>
<h2>现在是否值得投资 1,000 美元购买礼来公司股票？</h2>
<p>在考虑是否购买礼来公司股票之前，您需要听到这个。</p>
<p>MarketBeat 每天跟踪华尔街评级最高、表现最佳的研究分析师以及他们向客户推荐的股票。MarketBeat 已经确定了五支顶级分析师悄悄告诉他们的客户在更广泛市场注意之前现在购买的股票...而礼来公司不在名单上。</p>
<p>尽管礼来公司目前在分析师中有 “中等买入” 评级，但顶级分析师认为这五支股票更值得购买。</p>
<p>查看这五支股票</p>

礼来

<p>礼来（Eli Lilly and Company，NYSE:LLY）股价在午盘交易中上涨了 0.6%。该公司股票的最高交易价为 878.09 美元，最后交易价为 872.34 美元。股票交易量有所下降。几份研究报告将该股评为 “中等买入”，平均目标价为 787.53 美元。礼来最近宣布了季度股息。内部人士已经抛售了大量公司股票</p>

<p>Shares of Eli Lilly and Company (NYSE:LLY - Get Free Report) were up 0.6% during mid-day trading on Thursday . The stock traded as high as $878.09 and last traded at $872.34. Approximately 603,843 shares changed hands during trading, a decline of 79% from the average daily volume of 2,942,490 shares. The stock had previously closed at $867.30.</p>
<div class="lb-trans"><p>周四午盘，礼来公司（NYSE:LLY）股价上涨 0.6%。股价最高达到 878.09 美元，最后交易价为 872.34 美元。约 603,843 股股票在交易中换手，较日均成交量 2,942,490 股下降了 79%。股价前一交易日收盘价为 867.30 美元。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>礼来公司</strong> 的提醒：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<ul>
<li>Hims &amp; Hers Health Soars on Generic GLP-1 Rollout Plans</li>
</ul>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
<ul>
<li>Hims &amp; Hers Health 因通用 GLP-1 推出计划而飙升</li>
</ul>
</div><p>LLY has been the topic of several recent research reports. Cantor Fitzgerald restated an &#34;overweight&#34; rating and issued a $885.00 price target on shares of Eli Lilly and Company in a research note on Tuesday. Morgan Stanley upped their price target on Eli Lilly and Company from $805.00 to $950.00 and gave the company an &#34;overweight&#34; rating in a report on Friday, February 16th. Argus boosted their target price on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, May 14th. Truist Financial upped their target price on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday, May 1st. Finally, Jefferies Financial Group boosted their price target on Eli Lilly and Company from $925.00 to $957.00 and gave the company a &#34;buy&#34; rating in a report on Friday, June 7th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. Based on data from MarketBeat, Eli Lilly and Company presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $787.53.</p>
<div class="lb-trans"><p>LLY 股票近期成为多份研究报告的讨论焦点。坎特菲茨杰尔德（Cantor Fitzgerald）重申对礼来公司的 “超重” 评级，并在周二的研究报告中给出了每股 885.00 美元的目标价位。根据 2 月 16 日星期五的一份报告，摩根士丹利（Morgan Stanley）将礼来公司的目标价从 805.00 美元上调至 950.00 美元，并给予该公司 “超重” 评级。阿格斯（Argus）将礼来公司的目标价从 770.00 美元提高至 840.00 美元，并在 5 月 14 日星期二的研究报告中给予该公司 “买入” 评级。Truist Financial 将礼来公司的目标价从 850.00 美元上调至 892.00 美元，并在 5 月 1 日星期三的报告中给予该公司 “买入” 评级。最后，杰富瑞金融集团（Jefferies Financial Group）将礼来公司的目标价从 925.00 美元上调至 957.00 美元，并在 6 月 7 日星期五的报告中给予该公司 “买入” 评级。三位研究分析师对该股票给予持有评级，而 17 位对该公司股票给予买入评级。根据 MarketBeat 的数据，礼来公司目前的共识评级为 “中度买入”，平均目标价为 787.53 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Eli Lilly and Company</strong></p>
<div class="lb-trans"><p><strong>查看我们对礼来公司的最新股票分析</strong></p>
</div><h2>Eli Lilly and Company Stock Up 1.1 %</h2>
<ul>
<li>4 Stocks Making New Highs Despite Market Weakness</li>
</ul>
<div class="lb-trans"><h2>礼来公司股价上涨 1.1%</h2>
<ul>
<li>尽管市场疲软，4 只股票创下新高</li>
</ul>
</div><p>The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. The company has a 50-day simple moving average of $781.80 and a 200 day simple moving average of $714.39. The company has a market cap of $833.23 billion, a P/E ratio of 129.19, a P/E/G ratio of 1.89 and a beta of 0.36.</p>
<div class="lb-trans"><p>该公司当前比率为 1.35，速动比率为 1.03，负债权益比为 1.90。公司的 50 天简单移动平均线为 781.80 美元，200 天简单移动平均线为 714.39 美元。公司市值为 8332.3 亿美元，市盈率为 129.19，市盈增长比率为 1.89，贝塔系数为 0.36。</p>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, topping analysts' consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The firm had revenue of $8.77 billion for the quarter, compared to analysts' expectations of $8.94 billion. During the same period in the prior year, the business posted $1.62 earnings per share. The business's revenue for the quarter was up 26.0% on a year-over-year basis. On average, equities analysts anticipate that Eli Lilly and Company will post 13.76 EPS for the current year.</p>
<div class="lb-trans"><p>礼来公司（NYSE:LLY）于 5 月 6 日星期一发布了季度收益报告。公司报告季度每股盈利为 2.58 美元，超过分析师预期的 2.53 美元，超出 0.05 美元。礼来公司的净利润率为 17.08%，净资产收益率为 56.98%。该季度公司收入为 877 亿美元，低于分析师预期的 894 亿美元。与去年同期相比，该季度业务收入增长了 26.0%。股票分析师平均预计，礼来公司今年将实现每股盈利 13.76 美元。</p>
</div><h2>Eli Lilly and Company Announces Dividend</h2>
<ul>
<li>LifeMD Can Surge on Its GLP-1 Offerings</li>
</ul>
<div class="lb-trans"><h2>礼来公司宣布股息</h2>
<ul>
<li>LifeMD 因其 GLP-1 产品而大涨</li>
</ul>
</div><p>The company also recently announced a quarterly dividend, which was paid on Monday, June 10th. Shareholders of record on Thursday, May 16th were issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 0.59%. The ex-dividend date was Wednesday, May 15th. Eli Lilly and Company's dividend payout ratio is 76.58%.</p>
<div class="lb-trans"><p>公司最近宣布了季度股息，股息于 6 月 10 日星期一支付。截至 5 月 16 日星期四持股的股东将获得 1.30 美元的股息。这代表每年 5.20 美元的股息和股息率为 0.59%。除息日为 5 月 15 日星期三。礼来公司的股息支付比率为 76.58%。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部交易活动</h2>
</div><p>In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 92,563 shares of the stock in a transaction dated Friday, May 24th. The shares were sold at an average price of $809.21, for a total transaction of $74,902,905.23. Following the transaction, the insider now directly owns 98,556,247 shares in the company, valued at approximately $79,752,700,634.87. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, CAO Donald A. Zakrowski sold 750 shares of the business's stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the transaction, the chief accounting officer now owns 7,130 shares in the company, valued at approximately $5,842,821.10. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Lilly Endowment Inc sold 92,563 shares of the firm's stock in a transaction that occurred on Friday, May 24th. The shares were sold at an average price of $809.21, for a total transaction of $74,902,905.23. Following the completion of the sale, the insider now owns 98,556,247 shares of the company's stock, valued at $79,752,700,634.87. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 552,804 shares of company stock worth $462,119,714. Company insiders own 0.13% of the company's stock.</p>
<div class="lb-trans"><p>在其他礼来公司新闻中，主要股东礼来基金会（Lilly Endowment Inc）于 5 月 24 日星期五以 809.21 美元的平均价格出售了 92,563 股股票。交易总额为 74,902,905.23 美元。交易后，该内部人士现在直接持有公司中的 98,556,247 股股票，价值约 79,752,700,634.87 美元。该交易已在提交给证券交易委员会的文件中披露，可通过此超链接访问。此外，首席会计官唐纳德·A·扎克罗斯基（Donald A. Zakrowski）于 6 月 3 日星期一以 819.47 美元的平均价格出售了 750 股公司股票。交易总额为 614,602.50 美元。交易完成后，首席会计官现在持有公司 7,130 股股票，价值约 5,842,821.10 美元。该交易已在提交给证券交易委员会的文件中披露，可通过此超链接访问。此外，主要股东礼来基金会于 5 月 24 日星期五以 809.21 美元的平均价格出售了 92,563 股公司股票。交易总额为 74,902,905.23 美元。交易完成后，该内部人士现在持有公司 98,556,247 股股票，价值 79,752,700,634.87 美元。有关此次交易的披露可在此处找到。过去 90 天内，内部人士已出售 552,804 股价值 462,119,714 美元的公司股票。公司内部人士持有公司股票的比例为 0.13%。</p>
</div><h2>Institutional Trading of Eli Lilly and Company</h2>
<div class="lb-trans"><h2>礼来公司的机构交易</h2>
</div><p>A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its position in Eli Lilly and Company by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 72,745,011 shares of the company's stock worth $56,592,709,000 after buying an additional 1,133,810 shares during the last quarter. Capital World Investors raised its stake in shares of Eli Lilly and Company by 0.3% during the 4th quarter. Capital World Investors now owns 26,949,773 shares of the company's stock valued at $15,709,466,000 after buying an additional 89,720 shares during the last quarter. Morgan Stanley lifted its holdings in shares of Eli Lilly and Company by 0.7% in the 3rd quarter. Morgan Stanley now owns 12,545,572 shares of the company's stock valued at $6,738,605,000 after buying an additional 83,915 shares during the period. Norges Bank acquired a new stake in Eli Lilly and Company in the 4th quarter valued at $5,992,890,000. Finally, Northern Trust Corp increased its holdings in Eli Lilly and Company by 3.6% in the 3rd quarter. Northern Trust Corp now owns 10,158,275 shares of the company's stock worth $5,456,314,000 after acquiring an additional 355,317 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.</p>
<div class="lb-trans"><p>最近，许多机构投资者对礼来公司的持股进行了调整。Vanguard Group Inc.在第一季度将其在礼来公司的持股比例提高了 1.6%。Vanguard Group Inc.在上个季度购买了额外的 1,133,810 股股票后，现在拥有公司的 72,745,011 股股票，价值 565.92709 亿美元。Capital World Investors 在第四季度将其对礼来公司股票的持股比例提高了 0.3%。Capital World Investors 在上个季度购买了额外的 89,720 股股票后，现在拥有公司的 26,949,773 股股票，价值 157.09466 亿美元。摩根士丹利在第三季度将其对礼来公司股票的持股比例提高了 0.7%。摩根士丹利在该期间购买了额外的 83,915 股股票后，现在拥有公司的 12,545,572 股股票，价值 67.38605 亿美元。挪威中央银行在第四季度收购了价值 59.9289 亿美元的礼来公司新股份。最后，Northern Trust Corp 在第三季度将其对礼来公司的持股比例提高了 3.6%。Northern Trust Corp 在上个季度额外增持了 355,317 股股票后，现在拥有公司的 10,158,275 股股票，价值 54.56314 亿美元。机构投资者和对冲基金拥有公司股份的 82.53%。</p>
</div><h2>Eli Lilly and Company Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>礼来公司公司简介（获取免费报告）</h2>
</div><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p>
<div class="lb-trans"><p>礼来公司在全球范围内发现、开发和销售人类药品。该公司为糖尿病提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素利斯普罗、胰岛素利斯普罗胺、胰岛素利斯普罗混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500；为 2 型糖尿病提供 Jardiance、Mounjaro 和 Trulicity；为肥胖症提供 Zepbound。</p>
</div><h2>Recommended Stories</h2>
<ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>How to Use the MarketBeat Excel Dividend Calculator</li>
<li>Dave &amp; Buster’s Stock Offers a Prime Buying Opportunity</li>
<li>Dividend Payout Ratio Calculator</li>
<li>The FOMC Decision Means Higher Prices for Stocks This Summer</li>
<li>Dividend Capture Strategy: What You Need to Know</li>
<li>Here's Why Analysts Boosted Walmart Stock's Valuation</li>
</ul>
<div class="lb-trans"><h2>推荐故事</h2>
<ul>
<li>五支我们比礼来公司更喜欢的股票</li>
<li>如何使用 MarketBeat Excel 股息计算器</li>
<li>戴夫与巴斯特股票提供了一个主要的购买机会</li>
<li>股息支付比率计算器</li>
<li>FOMC 决定意味着今年夏天股票价格上涨</li>
<li>股息捕捉策略：你需要了解的</li>
<li>分析师为什么提高了沃尔玛股票的估值</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由 Narrative Science 技术和 MarketBeat 的财务数据生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队的审核。请将有关本故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ The Key to this $10 Trillion Tech Boom (From Porter &amp; Company)(Ad)</p>
<div class="lb-trans"><p>→ 这个 10 万亿美元科技繁荣的关键（来自 Porter &amp; Company）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MzM4" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8338&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Eli Lilly and Company right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资 1,000 美元购买礼来公司股票？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑是否购买礼来公司股票之前，您需要听到这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街评级最高、表现最佳的研究分析师以及他们向客户推荐的股票。MarketBeat 已经确定了五支顶级分析师悄悄告诉他们的客户在更广泛市场注意之前现在购买的股票...而礼来公司不在名单上。</p>
</div><p>While Eli Lilly and Company currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管礼来公司目前在分析师中有 “中等买入” 评级，但顶级分析师认为这五支股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五支股票</p>
</div>